Type 1 diabetes (T1D) is a chronic autoimmune disorder in which the immune system selectively destroys the insulin-producing beta cells of the pancreatic islets. This destruction leads to an absolute deficiency of insulin, requiring lifelong exogenous insulin therapy. For decades, research has focused primarily on the roles of T cells, B cells, and autoantibodies in beta cell destruction. However, growing evidence implicates the innate immune system, particularly the complement system, as a critical contributor to the initiation and amplification of autoimmunity in T1D. Understanding the interplay between complement activation and islet autoimmunity not only deepens our knowledge of disease pathogenesis but also opens new avenues for therapeutic intervention. This article provides an expanded overview of the complement system's role in T1D and examines current and emerging strategies for targeting complement to preserve beta cell function.

Complement System Fundamentals

The complement system is an evolutionarily ancient component of innate immunity composed of more than 30 soluble and membrane-bound proteins. These proteins circulate in an inactive state and become activated in a tightly regulated cascade upon encountering pathogens, damaged cells, or other danger signals. The complement cascade can be triggered through three distinct initiation pathways—the classical, lectin, and alternative pathways—each converging at the cleavage of C3, a central component. The classical pathway is typically activated by antigen-antibody complexes (IgG or IgM) binding to C1q. The lectin pathway is initiated by mannose-binding lectin or ficolins recognizing carbohydrate patterns on microbes. The alternative pathway undergoes continuous low-level spontaneous activation and can be amplified on surfaces that lack regulatory proteins.

Activation of C3 generates C3a and C3b, which mediate several effector functions: C3b opsonizes targets for phagocytosis, C3a acts as an anaphylotoxin promoting inflammation, and further cascade steps lead to the formation of C5 convertase, generating C5a (a potent chemoattractant) and C5b. The assembly of C5b with C6, C7, C8, and multiple C9 molecules forms the membrane attack complex (MAC), a pore that inserts into cell membranes and causes osmotic lysis. Host cells are protected from accidental complement attack by a battery of regulatory proteins such as CD55 (decay-accelerating factor), CD59 (protectin), factor H, and factor I, which inactivate complement components at various steps.

In healthy individuals, complement functions as a precise surveillance system, eliminating pathogens and clearing cellular debris while maintaining self-tolerance. Dysregulation of this system—whether due to genetic variants, chronic inflammation, or autoimmune processes—can lead to unintended damage to host tissues. An increasing body of research connects such dysregulation to the pathogenesis of several autoimmune diseases, including rheumatoid arthritis, systemic lupus erythematosus, and now T1D.

Complement in T1D Pathogenesis

Genetic Associations

Multiple lines of evidence link complement system components to T1D susceptibility. Genome-wide association studies have identified risk loci near complement-related genes, including those encoding C4, C3, and regulators such as CFH and CFHR gene cluster. The major histocompatibility complex (MHC) region on chromosome 6, which contains the genes for C4A and C4B (components of the classical pathway C3 convertase), shows strong association with T1D. Low copy number of C4 genes, leading to reduced C4 protein levels, has been reported in individuals with T1D and may compromise the clearance of immune complexes, thereby promoting autoimmunity. Similarly, variants in the CFH gene have been linked to altered regulation of the alternative pathway, suggesting a genetic predisposition to uncontrolled complement activation in the islet microenvironment.

Complement Activation Products in Serum and Tissues

Numerous studies have reported elevated levels of complement activation fragments, such as C3a, C5a, and the soluble MAC (sC5b-9), in the circulation of individuals with recent-onset T1D compared to healthy controls. Increased plasma C3d, a degradation product of C3b, has also been observed and correlates with markers of islet autoimmunity. In histological analyses of pancreata from T1D organ donors, complement proteins including C4d and C3d are deposited in and around islets, co-localizing with areas of beta cell destruction. These deposits indicate that complement activation occurs locally at the target tissue and is not merely a systemic epiphenomenon. The persistence of complement activation products after clinical diagnosis suggests that ongoing complement-mediated damage may contribute to the progressive loss of residual beta cell mass even years after onset.

Islet Autoantibodies and Complement Fixation

Autoantibodies against insulin, glutamic acid decarboxylase (GAD65), islet antigen-2 (IA-2), and zinc transporter 8 (ZnT8) are hallmark serological markers of T1D. Importantly, many of these autoantibodies are capable of fixing complement, i.e., binding to C1q and initiating the classical pathway. Studies have shown that complement-fixing islet autoantibodies are more strongly associated with rapid disease progression than non-fixing antibodies. For example, autoantibodies of the IgG1 subclass, which have high affinity for C1q, are particularly enriched in individuals who progress to clinical T1D within a few years. This suggests that the classical pathway activation driven by autoantibody-antigen complexes on the surface of beta cells is an important effector mechanism of beta cell injury.

Beta Cell Vulnerability to Complement Attack

Beta cells are intrinsically susceptible to complement-mediated injury because they express relatively low levels of membrane-bound complement regulatory proteins (e.g., CD55 and CD59) compared to other cell types. Under proinflammatory conditions, such as exposure to cytokines like interferon-γ and tumor necrosis factor-α, the expression of these regulators may be further downregulated, rendering beta cells even more vulnerable to MAC formation and lysis. In addition, beta cells themselves can produce complement components, including C3, factor B, and factor D, under stress conditions, thereby amplifying local complement activation in a vicious cycle. This unique susceptibility underscores why complement-targeted therapies might be particularly effective in preserving beta cell mass.

Mechanisms of Complement-Mediated Beta Cell Destruction

Inflammation via Anaphylotoxins

The generation of C3a and C5a during complement activation has profound proinflammatory effects. These anaphylotoxins bind to their respective receptors (C3aR, C5aR1, and C5aR2) expressed on a variety of immune cells, including mast cells, macrophages, neutrophils, and dendritic cells. In the context of T1D, C5a promotes the recruitment of inflammatory myeloid cells to the islets, enhances the production of reactive oxygen species and proteolytic enzymes, and stimulates the release of cytokines such as IL-1β and TNF-α. These cytokines are directly toxic to beta cells and also upregulate MHC class I expression, making beta cells more visible to autoreactive CD8+ T cells. The anaphylotoxin-driven inflammatory milieu thus acts as a bridge between innate and adaptive immune responses, amplifying autoimmune destruction.

Opsonization and Phagocytosis

Deposition of C3b and its breakdown products (iC3b, C3dg) on the surface of beta cells serves as a powerful opsonin, marking these cells for elimination by phagocytes expressing complement receptors (CR1, CR3, CR4). Macrophages and dendritic cells in the peri-islet area can engulf opsonized beta cell debris or even intact cells, processing and presenting beta cell antigens to T cells. This antigen presentation further fuels the adaptive autoimmune response, creating a feedback loop that sustains and amplifies beta cell destruction. Studies using murine models of T1D have shown that depletion of complement or blockade of C3 reduces the capacity of dendritic cells to cross-present islet antigens and delays disease onset.

Membrane Attack Complex-Mediated Lysis

The assembly of the membrane attack complex on the beta cell plasma membrane results in direct cell death by necrosis. Given the low expression of CD59 (which prevents MAC insertion) on beta cells, these cells are highly susceptible to MAC-dependent lysis. In vitro experiments demonstrate that exposure of human islets to complement-fixing serum from T1D patients induces rapid beta cell death, which can be inhibited by blocking C5 cleavage or by adding exogenous CD59. Histological examination of pancreata from T1D patients also reveals MAC deposits on remaining beta cells, supporting the relevance of this lytic mechanism in vivo.

Crosstalk with Adaptive Immunity

Beyond direct effector functions, complement activation influences adaptive immune responses in multiple ways. C3a and C5a modulate T cell differentiation and survival: C5aR signaling on T cells promotes Th1 and Th17 responses while suppressing regulatory T cell (Treg) activity. This skews the immune balance away from tolerance and toward autoimmunity. Additionally, complement fragments enhance B cell activation and antibody production, including the generation of complement-fixing autoantibodies. The interaction of C3d with complement receptor 2 (CD21) on B cells provides a potent co-stimulatory signal that lowers the threshold for B cell activation, thereby promoting the expansion of autoreactive B cell clones. Thus, complement serves as a central amplifier of both the innate and adaptive arms of autoimmunity in T1D.

Therapeutic Targeting of Complement in T1D

Given the mounting evidence for complement's role in T1D pathogenesis, a variety of therapeutic strategies are being explored to dampen complement activation while preserving essential host defense functions. These approaches are in preclinical development or early clinical trials, and they aim to intervene at different steps of the cascade.

C1 Inhibitors

C1 esterase inhibitor (C1-INH) is a naturally occurring serine protease inhibitor that blocks the classical and lectin pathways by inactivating C1r, C1s, and MASP-2. Recombinant human C1-INH (conestat alfa) is approved for hereditary angioedema and is under investigation for various inflammatory conditions. In a mouse model of T1D, treatment with C1-INH reduced complement activation, decreased insulitis, and preserved beta cell function. A pilot study in humans with recent-onset T1D showed that C1-INH administration was safe and appeared to lower C4d deposition in islets, though larger trials are needed to assess efficacy.

C3 and C5 Inhibitors

Inhibiting at the level of C3 or C5 can provide broad suppression of complement effector functions. The C3 inhibitor compstatin and its analog (AMY-101) block the cleavage of C3, preventing generation of all downstream fragments. In non-obese diabetic (NOD) mice, AMY-101 delayed the onset of diabetes and reduced insulitis. C5 inhibitors, such as eculizumab (a monoclonal antibody against C5) and ravilizumab, block the formation of C5a and MAC while preserving upstream opsonization (a potential advantage for maintaining pathogen clearance). Eculizumab is approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome. Preclinical studies in NOD mice and humanized mouse models suggest that C5 blockade reduces beta cell loss and enhances engraftment of transplanted islets. However, the high cost and need for chronic intravenous administration pose barriers for T1D.

Soluble Complement Receptor 1 (sCR1)

sCR1 (also known as TP10) is a recombinant soluble form of the complement receptor CR1 that acts as a decoy receptor, blocking all three activation pathways by accelerating the decay of C3 and C5 convertases. In animal models of T1D, sCR1 treatment reduced complement deposition on islets and improved outcomes after islet transplantation. Its potential as a therapeutic for autoimmune diabetes is being explored, although clinical development has been limited.

Modulating Complement Regulators

Rather than directly inhibiting activation, another strategy is to enhance endogenous complement regulation. This can be achieved by delivering recombinant regulatory proteins (e.g., soluble factor H, soluble CD55) or by upregulating expression of membrane regulators on beta cells using gene therapy. For instance, transgenic overexpression of CD59 in beta cells in NOD mice protected against complement-mediated lysis and reduced diabetes incidence. The success of such approaches will depend on efficient and targeted delivery without causing global immunosuppression or toxicity.

RNA Interference and Gene Editing

Advances in RNA interference (RNAi) and CRISPR/Cas9 gene editing open possibilities for silencing complement genes specifically in tissues involved in T1D. siRNA targeting C3 or C5 could be delivered to the pancreas using nanoparticle carriers, reducing local complement activation without systemic effects. In a recent proof-of-concept study, intraductal administration of C5-targeting siRNA in a rat model of T1D decreased complement deposition and preserved beta cell mass. Gene editing could also be employed to correct complement regulatory deficiencies in patient-derived induced pluripotent stem cells before differentiation into beta cells for transplantation. These technologies are still in the early stages but hold promise for personalized intervention.

Challenges and Considerations

Risk of Infection

Complement plays an essential role in the defense against encapsulated bacteria, particularly Neisseria meningitidis. Long-term systemic inhibition of C3 or C5 significantly increases the risk of meningococcal and other infections, as observed in patients treated with eculizumab. For T1D patients, who are typically otherwise immunocompetent, this risk must be carefully weighed against potential benefits. Vaccination against Neisseria meningitidis and antibiotics prophylaxis are mandatory for patients receiving C5 inhibitors. Targeting complement more selectively in the pancreatic microenvironment—for example via local delivery or tissue-specific inhibitors—could mitigate infection risk while still conferring therapeutic benefit.

Timing of Intervention

Complement activation appears to be an early event in T1D pathogenesis, occurring even before the appearance of glycemic abnormalities. Interventions that block complement may be most effective if initiated during the preclinical phase, in individuals positive for multiple autoantibodies who have high risk of progressing to clinical disease. This window of opportunity, known as stage 1 or stage 2 T1D, aligns with ongoing efforts to screen at-risk populations. However, designing trials with prevention endpoints requires long follow-up and large sample sizes, making them challenging to execute.

Biomarkers for Monitoring

To evaluate the efficacy of complement-targeted therapies, reliable biomarkers of complement activation and beta cell health are needed. Measurement of plasma C3a, C5a, and sC5b-9 can indicate systemic complement activation. More specific markers, such as C4d deposition on islet cells (assessable via biopsy or possibly imaging), could provide direct evidence of target engagement. Additionally, monitoring of autoantibody titers, C-peptide levels, and glycemic control will remain standard endpoints for clinical trials. Advances in mass spectrometry and proteomics may yield new biomarkers to refine patient selection and response assessment.

Future Directions

Clinical Trials

Despite the promising preclinical data, only a handful of clinical trials have evaluated complement inhibition in T1D. A phase 2 trial of the C1 inhibitor conestat alfa in recent-onset T1D (CTRI/2020/05/025407) is underway. Another trial is investigating the safety of the C5 inhibitor eculizumab in combination with immunosuppressive therapy for islet transplantation. The field eagerly awaits results from these studies. Future trials will likely explore combination therapies that block complement concurrently with other immune checkpoints, such as anti-CD3 or Treg-inducing agents, to achieve durable tolerance with minimal side effects.

Combination Therapies

Given the complexity of T1D autoimmunity, single-agent complement inhibition may not be sufficient to halt beta cell destruction. Combining complement inhibitors with agents that target T cell co-stimulation (e.g., abatacept) or B cell depletion (e.g., rituximab) could synergistically suppress both innate and adaptive immunity. Preclinical studies combining anti-C5 antibody with low-dose rapamycin showed superior preservation of beta cell mass in NOD mice compared to either monotherapy. Designing rational combinations that maximize efficacy while minimizing overlapping toxicities will be a key challenge for the next wave of clinical trials.

Personalized Medicine

Genetic polymorphisms in complement components and regulators may affect an individual's baseline complement activity and response to therapy. For example, patients with low C4 copy number might benefit more from classical pathway inhibition, while those with CFH variants might require alternative pathway blockade. Biomarker-based stratification could enable personalized treatment regimens, enhancing therapeutic outcomes and reducing unnecessary exposure. The integration of genomics, proteomics, and metabolomics into T1D clinical care will facilitate this precision immunology approach.

Conclusion

The complement system plays a multifaceted and non-redundant role in the immunopathogenesis of type 1 diabetes. From initiating inflammation via anaphylotoxins to opsonizing beta cells for destruction and enhancing adaptive immune responses, complement activation contributes at virtually every stage of autoimmune beta cell killing. Genetic associations, histological deposits, and functional studies all converge to implicate complement as both a driver and amplifier of T1D. As our understanding of the mechanisms deepens, a range of therapeutic strategies—including C1 inhibitors, anti-C5 antibodies, soluble regulators, and gene therapy—are being developed to safely modulate complement in T1D. While challenges related to infection risk, optimal timing, and monitoring remain, the potential for complement-targeted interventions to preserve residual beta cell function and even prevent disease onset is substantial. Continued research, particularly well-designed clinical trials, will be essential to translate these insights into meaningful advances for individuals at risk for or living with type 1 diabetes.